The Food and Drug Administration grants emergency use authorization for Eli Lilly and Company's combination antibodytherapy (bamlanivimaband etesevimab) for use in positive adults and children aged 12 and older who are at high risk of severe disease.
The Food and Drug Administration grants emergency use authorization for Eli Lilly and Company's combination antibodytherapy bamlanivimab-etesevimab for use inCOVID-19 positive adults and children aged 12 and older who are at high risk of severe disease.